NFKB1 and Alzheimer disease: In China, based on the study involved in 52 patients with mild and moderate AD, the treatment with modified Shuyu Pill could effectively improve the cognitive function of the patients with mild and moderate AD and the underlying mechanism may be related to inhibiting the expressions of IL-1β/NF-κB/miR-146a in peripheral blood (37).